New anabolic agents in the treatment of osteoporosis.
Hough
Stephen
S
Endocrine Unit, Department of Medicine, University of Stellenbosch.
D045930:Anabolic Agents / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D012969:Sodium Fluoride / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D045930:Anabolic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009942:Organometallic Compounds; D010281:Parathyroid Hormone; D013876:Thiophenes; C081587:strontium ranelate; D007334:Insulin-Like Growth Factor I; D012969:Sodium Fluoride; D013006:Growth Hormone